London-based Ternary Therapeutics bets AI-designed ‘molecular glues’ can tame chronic inflammation, opening new doors for longevity medicine.
London-based Ternary Therapeutics has raised $4.4 million (€4.1 million) in a seed round led by Paris-based VC daphni, alongside Pace Ventures, i&i Biotech Fund and Future Planet Capital. On paper, a $4.4 million seed may seem modest, but in today’s biotech climate, it is more like a mark of selective confidence. Investors are willing to back a company that promises to tackle one of the trickiest problems in drug discovery.
Ternary is venturing into targeted protein degradation, a field that has generated excitement but also frustration. Instead of the standard “lock-and-key” drugs that block proteins, Ternary is designing molecular glues [1]. These are small molecules that can bring two proteins together, nudging a harmful protein into the cell’s natural disposal system or modulating biology in ways conventional drugs often cannot.
It’s like matchmaking for proteins. Instead of fighting the problem head-on, you persuade the system to fix it itself. It’s a subtle but powerful approach, especially for proteins linked to stubborn inflammatory diseases.
Ternary’s initial focus is inflammation and neuroinflammation – areas that resonate far beyond classic immune diseases. Chronic, low-level inflammation, sometimes called “inflammaging,” is now understood as one of the key processes driving age-related decline, from neurodegeneration to metabolic disorders. Tackling it effectively could be a gateway to healthier aging.
Tools capable of more precisely modulating those proteins might eventually transform our perspective on age-related diseases. Ternary is still in preclinical stages, but the implications for longevity medicine are hard to ignore. Better control of inflammation could help people age with less chronic disease burden.
Historically, molecular glues have been discovered largely by accident. A promising compound would appear in the lab by chance, and researchers would reverse-engineer why it worked. That makes the field exciting but unpredictable. Ternary aims to change that.
Its platform uses AI combined with physics-informed modeling and lab validation in a “closed loop.” In practical terms, the AI suggests potential glue molecules, the lab tests them and the results feed back into the system to refine the next round. The goal: a repeatable engine for designing drugs rather than relying on luck.
Biotech investment has changed. Investors now favor companies that demonstrate rigorous, defensible science rather than flashy AI slides. Ternary’s pitch hits both boxes – a clear AI-driven approach tied directly to tangible biology, rather than an abstract algorithm chasing any possible drug target.
The appointment of Ian Taylor to Ternary’s board strengthens the story. Taylor, former president of R&D at US-based Arvinas, brings credibility in the protein degradation space – a field that has faced both clinical and commercial setbacks. His presence signals that Ternary is serious about turning platform science into drugs that could reach the clinic.
Even with strong backing, the timing is notable. California-based f5 Therapeutics recently shut down after six years, citing the harsh funding environment for early-stage biotech. Ternary’s success in securing investors despite this reflects growing confidence in European techbio, particularly companies addressing “hard modality” challenges rather than applying AI superficially.
Chronic inflammation is a cornerstone of aging biology. The idea that AI-designed molecules could selectively modulate proteins linked to inflammaging is more than a lab experiment – it’s a potential tool for healthier, longer lives.
Of course, the road from seed funding to actual therapies is long. Preclinical data must become partnerable insights, then clinical candidates, and eventually treatments that demonstrate safety and efficacy in humans. But Ternary’s story is already noteworthy: it signals a maturing biotech ecosystem in Europe, one that is willing to place bets on science-driven platforms with clear longevity relevance.
For our readers, the key takeaway is this: the fight against age-related disease is increasingly looking like a computational and biological puzzle combined. Companies like Ternary are building the engines that could, one day, translate complex biology into actionable interventions – and perhaps, in time, allow us to age more gracefully.
